Following discontinuation of nucleot(s)ide analogue therapy, only about one-third of patients with HBeAg-negative chronic
hepatitis B (CHB) achieve disease remission, with rare HBsAg loss, as reported in a study. The likelihood of HBsAg loss and disease remission is high in the presence of very low HBsAg levels at baseline.